Pozen is ready to market Vimovo

Staff WriterJuly 1, 2009 

— Drugmaker Pozen announced that it has applied for marketing approval of its experimental treatment for arthritis.

The Chapel Hill company announced Tuesday that it has submitted a new drug application for Vimovo, previously known as PN 400, to the Food and Drug Administration.

The FDA's acceptance of the filing will trigger a $10 million milestone payment from pharmaceutical company AstraZeneca, which has licensed the marketing rights to Vimovo.

Cowen and Co. analyst Ian Sanderson projects that by 2013 Vimovo sales could reach $250 million in the U.S. market and $425 million worldwide.

If it wins FDA approval, Vimovo would be Pozen's second product. Its migraine drug, Treximet, is being marketed by GlaxoSmithKline.

Staff writer David Ranii

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service